EHA 2015: Pacritinib therapy led to myelofibrosis symptom improvement in patients without other medical options

EHA 2015: Pacritinib therapy led to myelofibrosis symptom improvement in patients without other medical options

EMJ

4 years
668 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3 (FLT3), is more effective than the best available therapy (BAT) at improving disease symptoms and quality of life (QoL) for patients with myelofibrosis. Patient-reported outcomes (PROs), which have become important for approval of new therapies, was also measured to determine whether pacritinib reduced patients symptom burden and helped them feel better. Presented by Ruben Mesa, MD, FACP, Mayo Clinic, Scottsdale, AZ, at the 20th Congress of the European Hematology Association (EHA) European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Treatment-Free Survival, With and Without Toxicity
Treatment-Free Survival, With and Without Toxicity
Category: Kidney Cancer
0 Views
kidneycancer 40 minutes
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Phase 2 Study of Lenvatinib Plus Pembrolizumab for Disease Progression After PD-1/PD-L1
Category: Kidney Cancer
0 Views
kidneycancer 55 minutes
What's To Come in Modern Imaging Technology
What's To Come in Modern Imaging Technology
Category: Kidney Cancer
1 Views
kidneycancer 20 hours
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Moleculin Announces Additional Positive Interim Results from Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia
Category: Acute Myelogenous Leukemia
4 Views
Cancer-News 23 hours
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
Category: Breast Cancer
6 Views
Cancer-News 1 day
Modern Imaging Technology
Modern Imaging Technology
Category: Kidney Cancer
3 Views
kidneycancer 1 day
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
ASH Releases New Clinical Practice Guidelines on Immune Thrombocytopenia
Category: News
2 Views
Cancer-News 1 day
Management of Clinical Cases in Kidney Cancer
Management of Clinical Cases in Kidney Cancer
Category: Kidney Cancer
4 Views
kidneycancer 2 days
Kidney Cancer Program & SPORE
Kidney Cancer Program & SPORE
Category: Kidney Cancer
1 Views
kidneycancer 2 days
Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality
Researchers Find Common Measures of Immune Status, Inflammation Can Predict Mortality
Category: News
4 Views
Cleveland Clinic 2 days